Moreover, in ccRCC samples, FDX1 showed a higher expression in female patients than in male patients (Figure 3B); a higher expression in patients with lower histological tumor grade (G1 + G2) than in patients with higher histological tumor grade (G3 + G4) (Figure 3C); and a higher expression in patients with lower pathological tumor stage (Stage I + II) than in patients with higher pathological tumor stage (Stage III + IV) (Figure 3D). Here, FDX1 is linked to neoplasm.